Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail
Duke Box 103861, Durham, NC 27710
Phone
(919) 668-4615
Email address
daniel.george@duke.edu
Education and Training
- Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
- Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
- M.D., Duke University, 1992
Grants
- A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metas
- Outcomes Database to prospectivelY aSSEss changing therapY landscape in Renal Cell Carcinoma (ODYSSEY RCC)
- An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer
- ODYSSEY RCC
- Odyssey RCC
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
- Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
- ODYSSEY RCC
- Decreasing the Financial Burden for Patients with Advanced Prostate Cancer By Understanding Provider Decision-Making
- Reducing prostate cancer aggressiveness via aptamer-mediated nuclear delivery of splice-switching oligonucleotides
- Targeting glutamine utilization in therapy-resistant prostate cancer
- Therapeutic targeting of MESH1 in renal cell carcinoma
- Race-related germline genetic variation and response to secondary hormonal therapy in metastatic castration-resistant prostate cancer
- An IND-enabling Trial to Determine the Number and Volume of Injections Necessary for Adequate Distribution Throughout Cancer Metastases and to Validate Poliovirus Receptor (CD155) Expression in Prostate Cancer
- Race-Related Alternative Splicing: Novel Targets in Prostate Cancer
- Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer
- A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer
- Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
- A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC); Sponsor ¿ Memorial Sloan Kettering Cancer Center
- Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers
- A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies